Breaking News Instant updates and real-time market news.

OPTN

Optinose

$8.08

0.2 (2.54%)

07:06
12/10/18
12/10
07:06
12/10/18
07:06

Optinose announces first patient enrolled in XHANCE clinical trial

Optinose announced the enrollment of the first patient in a global clinical trial to evaluate the safety and efficacy of XHANCE nasal spray as a treatment for patients with Chronic Sinusitis. The trial is a randomized, double-blind, placebo-controlled study of approximately 400 patients across 50 sites. In addition, the company announced the enrollment of the first patient in a clinical trial to evaluate the safety and efficacy of XHANCE for treatment of adolescent pediatric patients with nasal polyps. The pediatric trial is a randomized, double-blind, placebo-controlled study of approximately 120 patients across 30 sites. "We are particularly pleased to be initiating our clinical program in pursuit of an indication for treatment of Chronic Sinusitis because we are aware of no approved drugs for that indication, and we believe there is a very large population in need of treatment," said Dr. Ramy Mahmoud, President and COO of Optinose. "We anticipate starting the second trial in the program in 2019 and hope to achieve the first ever approval for this indication."

  • 12

    Dec

OPTN Optinose
$8.08

0.2 (2.54%)

11/14/18
CANT
11/14/18
NO CHANGE
Target $27
CANT
Overweight
Optinose price target lowered to $27 from $30 at Cantor Fitzgerald
Cantor Fitzgerald analyst William Tanner lowered his price target for Optinose to $27 to reflect tempered near-term expectations for Xhance. The analyst, however, still believes Xhance will become an important therapy for treating nasal polyps. He finds it reasonable that the drug "will deliver evidence of safety and efficacy in other indications that would meaningfully expand the commercial opportunity." Tanner reiterates an Overweight rating on Optinose.
10/17/18
JEFF
10/17/18
NO CHANGE
Target $31
JEFF
Buy
Jefferies still sees 'major' opportunity for Optinose after Dupixent data
Optinose (OPTN) shares underperformed yesterday following the positive Phase 3 results for Sanofi (SNY) and Regeneron's (REGN) Dupixent in treating patients with chronic rhinosinusitis with nasal polyps, Jefferies analyst David Steinberg tells investors in a research note titled "Biologics Competitor as Expected; Real World Pricing Issues Likely to Limit Us." The analyst says that while Dupixent demonstrated strong efficacy, clinicians he's spoken with believe that the "massive" pricing disparity versus nasal steroids will likely result in payer "step edits" that could limit widespread adoption of the "expensive" biologics currently under development. Further, Dupixent's head-to-head comparison with Optinose's Xhance's "strong" efficacy profile is difficult, the analyst adds. Steinberg still sees a "major" long-term opportunity for Xhance and keeps a Buy rating on Optinose with a $31 price target.
08/31/18
JEFF
08/31/18
NO CHANGE
Target $31
JEFF
Buy
Jefferies sees prescription rebound for Optinose's Xhance
After meeting with Optinose management, Jefferies analyst David Steinberg says that despite the recent setback, he continues to believe that Xhance will become a large product. Post adjustments to Xhance launch tactics, management believes they have made the proper changes and expect prescriptions to reaccelerate as summer ends, Steinberg tells investors in a research note. He points out that the company highlighted positive physician and patient feedback on the performance of the drug. The analyst keeps a Buy rating on Optinose with a $31 price target.
08/14/18
PIPR
08/14/18
NO CHANGE
Target $30
PIPR
Overweight
Piper not worried by trajectory of Optinose's Xhance, stays Overweight
Piper Jaffray analyst David Amsellem says he's not worried about the growth trajectory of Optinose's Xhance with the stock down 31% following this morning's earnings report. There is understandably some concern that the company's focus on more aggressive co-pay assistance may hurt the drug's average selling price and the growth, Amsellem tells investors in an intraday research note. The analyst, however, views Optinose's transition away from the Xhance sampling program as positive and he expects the company to continue to execute on payer contracts. He lowered his price target for the shares to $30 from $34 and keeps an Overweight rating on Optinose.

TODAY'S FREE FLY STORIES

ET

Energy Transfer LP

$11.32

-0.3 (-2.58%)

06:19
11/19/19
11/19
06:19
11/19/19
06:19
Recommendations
Energy Transfer LP analyst commentary  »

Energy Transfer LP could…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CABA

Cabaletta Bio

$13.84

0.24 (1.76%)

06:19
11/19/19
11/19
06:19
11/19/19
06:19
Initiation
Cabaletta Bio initiated  »

Cabaletta Bio initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LIN

Linde plc

$209.11

-0.57 (-0.27%)

06:18
11/19/19
11/19
06:18
11/19/19
06:18
Hot Stocks
Linde plc increases prices, equipment rentals in North America »

Linde announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AME

Ametek

$97.30

-0.86 (-0.88%)

06:17
11/19/19
11/19
06:17
11/19/19
06:17
Recommendations
Ametek analyst commentary  »

Ametek price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIT

Applied Industrial Technologies

$61.73

-0.36 (-0.58%)

06:16
11/19/19
11/19
06:16
11/19/19
06:16
Recommendations
Applied Industrial Technologies analyst commentary  »

Applied Industrial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DOOR

Masonite

$69.20

-0.05 (-0.07%)

, AWI

Armstrong World

$98.41

-0.83 (-0.84%)

06:14
11/19/19
11/19
06:14
11/19/19
06:14
Recommendations
Masonite, Armstrong World, TopBuild analyst commentary  »

Nomura Instinet raises…

DOOR

Masonite

$69.20

-0.05 (-0.07%)

AWI

Armstrong World

$98.41

-0.83 (-0.84%)

BLD

TopBuild

$108.71

1.45 (1.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PGNY

Progyny

$24.89

1.095 (4.60%)

06:14
11/19/19
11/19
06:14
11/19/19
06:14
Initiation
Progyny initiated  »

Progyny initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIH

Aesthetic Medical

$7.06

0.08 (1.15%)

06:13
11/19/19
11/19
06:13
11/19/19
06:13
Initiation
Aesthetic Medical initiated  »

Aesthetic Medical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSA

Public Storage

$213.46

0.32 (0.15%)

06:11
11/19/19
11/19
06:11
11/19/19
06:11
Downgrade
Public Storage rating change  »

Public Storage downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSGN

MSG Networks

$18.50

0.405 (2.24%)

06:11
11/19/19
11/19
06:11
11/19/19
06:11
Downgrade
MSG Networks rating change  »

MSG Networks downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

BA

Boeing

$369.50

-2.05 (-0.55%)

06:10
11/19/19
11/19
06:10
11/19/19
06:10
Hot Stocks
Boeing says Ghana intends to relaunch airline with three 787-9 Dreamliners »

Boeing and the Republic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DUK

Duke Energy

$88.63

0.05 (0.06%)

06:09
11/19/19
11/19
06:09
11/19/19
06:09
Syndicate
Duke Energy 25M share Spot Secondary priced at $86.45 »

The deal range was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

PFSI

PennyMac Financial

$32.07

0.17 (0.53%)

06:08
11/19/19
11/19
06:08
11/19/19
06:08
Recommendations
PennyMac Financial analyst commentary  »

PennyMac Financial price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KLXE

KLX Energy

$7.36

-0.59 (-7.42%)

06:08
11/19/19
11/19
06:08
11/19/19
06:08
Hot Stocks
KLX Energy expects to report non-cash impairment charge of $45M-$60M »

Amin J. Khoury, CEO of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PGNY

Progyny

$24.89

1.095 (4.60%)

06:06
11/19/19
11/19
06:06
11/19/19
06:06
Initiation
Progyny initiated  »

Progyny initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KLXE

KLX Energy

$7.36

-0.59 (-7.42%)

06:06
11/19/19
11/19
06:06
11/19/19
06:06
Hot Stocks
KLX Energy to reduce force by 17% and take a Q3 charge of $13M »

KLX Energy Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KBR

KBR

$29.86

-0.205 (-0.68%)

06:06
11/19/19
11/19
06:06
11/19/19
06:06
Hot Stocks
KBR awarded $23.7M Navy contract modification for base operations support »

KBR announced it has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

WE

We Company

$0.00

(0.00%)

, SFTBF

SoftBank

$0.00

(0.00%)

06:06
11/19/19
11/19
06:06
11/19/19
06:06
Periodicals
SoftBank CEO says he wants WeWork to turn profit by 2021, Fast Company reports »

SoftBank (SFTBF) CEO…

WE

We Company

$0.00

(0.00%)

SFTBF

SoftBank

$0.00

(0.00%)

SFTBY

SoftBank

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HD

Home Depot

$238.98

1.64 (0.69%)

06:05
11/19/19
11/19
06:05
11/19/19
06:05
Hot Stocks
Breaking Hot Stocks news story on Home Depot »

Home Depot down 6.7%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 11

    Dec

FTNT

Fortinet

$103.80

2.31 (2.28%)

06:04
11/19/19
11/19
06:04
11/19/19
06:04
Recommendations
Fortinet analyst commentary  »

Fortinet analyst day…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 05

    Dec

  • 06

    Dec

  • 09

    Dec

  • 12

    Dec

PSA

Public Storage

$213.46

0.32 (0.15%)

06:04
11/19/19
11/19
06:04
11/19/19
06:04
Downgrade
Public Storage rating change  »

Public Storage downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CABA

Cabaletta Bio

$13.84

0.24 (1.76%)

06:04
11/19/19
11/19
06:04
11/19/19
06:04
Initiation
Cabaletta Bio initiated  »

Cabaletta Bio initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HD

Home Depot

$238.98

1.64 (0.69%)

06:04
11/19/19
11/19
06:04
11/19/19
06:04
Earnings
Home Depot backs FY19 EPS view of about $10.03, consensus $10.13 »

Home Depot updated its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 11

    Dec

PGNY

Progyny

$24.89

1.095 (4.60%)

06:02
11/19/19
11/19
06:02
11/19/19
06:02
Initiation
Progyny initiated  »

Progyny initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HD

Home Depot

$238.98

1.64 (0.69%)

06:02
11/19/19
11/19
06:02
11/19/19
06:02
Earnings
Home Depot reports Q3 EPS $2.53, consensus $2.52 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 11

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.